chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Client presented at vaccination site for her Pfizer COVID booster vaccine. Client reported she received Pfizer COVID dose #1 (4/2/21; lot: EW0150) at the clinic without any issues. Client reported with Pfizer COVID dose 2 (4/23/21; lot: EW0161) at the clinic, within five minutes she had difficulty breathing with her throat closing, SOB, & facial numbness (lasted 20 minutes). Client reported at the observation area for the 2nd dose, she was laid down, and drank juice and water provided. She stated no medicines given and no emergency number called. She reported she had dizziness and lightheadedness within four hours of Pfizer COVID dose 2 and she reported she ate before received her Pfizer COVID dose 2. She reported she stayed at the observation area for 45 minutes then her son drove her home. She stated she ate today at 1100 and drinking water while waiting for approval. She said she had fever for 48 hours (took Tylenol with help) for Pfizer COVID dose 2. Client also said she had chest pressure and chest pain started the next day after Pfizer COVID dose 2. She said she followed up with PCP after day 2 of her Pfizer COVID dose 2. She said her PCP told her it was normal reactions that she had and to continue taking Tylenol for her fever as needed. Had HTN and taking Lisinopril 20 mg daily. She took Lisinopril this morning. At 1230, PHN took client?s current vitals: BP 136/86, HR 100, O2 Sat. 96%. Client reported her normal BP is 130/80. Client is requesting Pfizer booster approval today. PHN submitted a medical consult via text message to clinical project coordinator, requesting to proceed with the Pfizer COVID booster vaccine. Per the doctor, approval to proceed with Pfizer COVID booster vaccine was obtained from medical consult team via text message from clinical project coordinator. Client received Pfizer COVID vaccine, LOT#: FF8841 on 11/14/21 at 1312 by RN. The client did not report any symptoms during the 30-minute observation period. PHN educated client on possible adverse reactions and when to seek EMS. Client verbalized understanding. Client left vaccination site at 1342 unassisted and with a steady gait.
Patient was injected with her first dose of COVID-19 vaccine. After administration, the patient was handed her screening sheet and told to drop it at the last station. As the patient was proceeding to the drop off station, another vaccinator asked her if she needed to be vaccinated. She said yes. He had her sit down and began to vaccinate her in the same arm she just received her first dose a few minutes earlier. The patient did not say anything to the vaccinator. It was the first vaccinator who saw what was happening , only after administration of the second first dose.  The doctor was notified immediately. The patient was monitored for 30 minutes given emergency instructions and told that we will follow-up with her in 24 hours. The patient left after 30 minutes with no signs or symptoms of an adverse reaction.
PT developed a RASH over the entire body the day after vaccination which worsened with time. Treated with Solu-medrol 125mg and Prednisone 10mg. PT is improving and is stable. Diagnosed as URTICARIA.
Very bad headache, weak and tired. Went back to bed slept several hours, ate lunch, went back to bed for another 3 hours. Had Prevnar and Flulaval Quad vaccines.
Fever (99.4), chills, aches, nausea, headache, low energy, sore arm starting 9 hours after 2nd dose. A little better 48 hours later, still have bad headache, low energy, feel hot but fever is gone. Haven't needed to go to doctor
Pt received Pfizer vaccines on 04/01/21 and 04/25/2021. Pt presented to the ED on 11/16/21 with complaints of SOB, cough, nasal congestion, fever, and fatigue. Pt was found to be COVID positive. CXR showed COVID pneumonia. Pt required supplemental oxygen leading to intubation. Pt was transferred to another Hospital for ECMO.
1 of 4 pts vaxed w/Td exp an inject site react of erythema & induration; MD visit-react 4 cm in diameter; resolved;
lightheadedness / dizziness; dry mouth; dry throat; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (lightheadedness / dizziness), DRY MOUTH (dry mouth) and DRY THROAT (dry throat) in an elderly patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (lightheadedness / dizziness), DRY MOUTH (dry mouth) and DRY THROAT (dry throat). The patient was treated with EPINEPHRINE (EPIPEN) at a dose of 1 dosage form. At the time of the report, DIZZINESS (lightheadedness / dizziness), DRY MOUTH (dry mouth) and DRY THROAT (dry throat) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product information was provided.
Event: I was seen in the Emergency Room June 9, 2022 for severe chest pain and elevated Troponin levels. Cardiology diagnosed me with Pericarditis.   Treatment: Treated with IV and oral NSAID's as well as follow up echocardiogram. No other source of infection noted before or at time of visit. Recent COVID vaccine identified as being a possible cause.  Outcome: recurrent chest pain for 2 weeks. Increased chance for possible reoccurring pericarditis in the future according to the doctors.
This is a spontaneous report from a contactable consumer reporting for herself. A 44-year-old non-pregnant female patient received her first dose of bnt162b2 (Pfizer-BioNTech COVID-19 mRNA vaccine, Formulation: Solution for injection, Batch/Lot number: EW0173), via an unspecified route of administration, administered into the left arm on May 26, 2021 12:00 pm (at the age of 44-year-old) as single dose for COVID-19 immunization. Prior to vaccination, the patient was not diagnosed with COVID-19 and since vaccination the patient has not been tested for COVID-19. No relevant past drug history reported. Concomitant medication included paracetamol (Tylenol) the day after the shot. The patient did not receive any other vaccines within four weeks prior to the COVID vaccination. On May 27, 2021, at around 12:00, the patient experienced, (it felt like) the base of her brain swelled. She woke up breathing heavy and also started losing a lot of hair. She was still losing globs of hair. The patient did not receive any treatment for the events and there was no prolonged hospitalization. The outcome of the events was reported as not resolved. Information on Lot/Batch number was available. Additional information has been requested.
a little sicky on and off mostly in his stomach but overall feels okay; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer (patient) reported for himself that a male patient of unspecified age received his first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 08Jan2021 at single dose for COVID-19 immunization. Medical history was not reported. Concomitant medication included blood thinner. Patient received the first dose of the COVID-19 vaccine yesterday (08Jan2021). He stated that he has been feeling "a little sicky on and off mostly in his stomach but overall feels okay." He stated that he forgot to mention to facility that he is on a blood thinner and saw this on the sheet he received after his shot. He would like to know if this will be an issue when he goes for his second dose. He also would like to know if he has any immunity to COVID-19. Specifically he stated that he wants to visit a friend who has cancer and he wants to know if there is a possibility of getting his friend sick since he has received the vaccine now. Outcome of the event was unknown.   Information on the lot/batch number has been requested.
She tested positive for COVID-19; She tested positive for COVID-19; This is a spontaneous report from a contactable healthcare professional (patient) via Pfizer sales representative. A 55-years-old female patient received her first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date not reported), via an unspecified route of administration on 22Dec2020 at a single dose for Covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient, who is a frontline medical worker, informed that she tested positive for COVID-19 today (28Dec2020). The patient stated that she was informed by her employee health division at (place) that she was exposed to a patient with COVID-19 prior to her vaccination. She asked to be contacted regarding the timing of her second dose in light of her current status. The outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: There is not a reasonable possibility that reported "tested positive for COVID-19" is related to BNT162B2 vaccine.  The patient exposed to a patient with COVID-19 before vaccination.
Atrial fibrillation; palpitations; This is a spontaneous report from a contactable other health professional. This other health professional reported similar events for 2 patients. This is the 2nd of 2 reports. A female patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient experienced atrial fibrillation and palpitations on unspecified dates. Caller said that the patient had the atrial fibrillation about the same length of time she developed atrial fibrillation after her vaccine. The outcome of the events were unknown.  Information on the lot/ batch number has been requested.; Sender's Comments: Based on the information currently available, a possible contributory role of the suspect drug to the reported event Atrial fibrillation cannot be completely excluded based on temporal association. This case will be re-assessed when additional information becomes available.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identifies as part of this review, as well as any appropriate action in response, will be promptly notifies to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-2021111497 same reporter and product, similar events with different patients
3-4 inch diameter rash on left arm around injection site. Not raised, itchy, or hot.
I had a funny taste in my mouth around September 13, 2022. I spoke with the doctor on September 21, 2022. The doctor prescribed Nystatin liquid. She indicated that my mouth looked dry like I had thrush or a yeast infection. I took it for 7 days, but it didn't make a difference. We changed toothpaste from Colgate to Sensodyne and stopped the room deodorizer. I also gargled longer which only added moisture to my mouth.  As the weeks and days went by, I noticed that I was unable to taste food properly. My tongue felt like sandpaper. Taste to certain foods were not the same. Particularly cheese and milk. Some meats also taste different. I never loss my appetite. The worst thing was the dry sandpaper like mouth. Finally at the end of March I was able to taste again. The sandpaper feeling lasted about 2 months. My doctor recommended bloodwork to see if we had covid but we did not complete. I am about 95% recovered.
Information has been received from a health care professional concerning a 15 year old white female with a peanut allergy, allergy to cats and rabbits, and allergies to Keflex and Cefzil who received her first dose of Gardasil on 03-Jul-2007.  On 02-Nov-2007 was vaccinated with her second dose of Gardasil (Lot #659437/1266U) in the left deltoid.  It was reported the patient experienced "hives (for) one week after the vaccine were given on 02-Nov-2007 and 03-Jul-2007".  The patient was treated with Benadryl and Bactroban.  Additional information has been requested. As per a follow up from the physician, there is no further information. No further infformation is expected.
A report has been received from Health Professional. The report concerns a patient, female consumer, who had been receiving FLUMIST QUADRIVALENT (Intranasal). FLUMIST QUADRIVALENT (intranasal) started on 10-Oct-2014. It was reported that patient was administered with 1/2 dose of FLUMIST. The outcome of the event of 1/2 dose FLUMIST administered for dose is unknown. The report was considered to be non-serious. Corrected report 23-Oct-2014 : Primary reporter was changed from consumer to health professional. Narrative updated. Corrected report 24-Oct-2014 : Periodic clock stop was updated.
Pt recv vax on 3/12/99; on 3/22/99 pt exp green diarrhea, fever > 102; dx=rotavirus
Patient started experiencing left sided facial weakness on 8/7/2016.  She was seen in office on 8/9/2016 after worsening symptoms and was diagnosed with Bell's Palsy.
About 5-10 minutes later patient began to have metallic taste in her mouth. She began to feel warm. Also began to feel some burning in her upper chest. Patient denies any swelling in her throat. She denied any difficulty swallowing or breathing. Patient does have history of a mini stroke in the past. Patient states since then she is become hypersensitive to phalanx. She denies any known allergies. She denies any allergies to any injectables or any vaccines. No known food allergies. No medication allergies. Patient denies any known history of panic attacks. Patient was questioning if this may be a panic attack.
While in observation area pt. became dizzy and light headed. Pt was taken to the tent and laid down. Pt. vomited, after that he felt relieved. Iced pack on forehead.
Overheated and almost passed out numerous times in an hour. Very achy, headache, nauseous, fatigued, high fever general pain all over body.
Patient had GI distress (N/V/diarrhea) on 12/25
COVID-19 treatment; COVID-19 treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 30Mar2021 as dose 1, single (Batch/Lot number: unknown), in right arm, on 20Apr2021 as dose 2, single (Batch/Lot number: unknown), in right arm and on 15Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 36 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergy: Penicillin" (unspecified if ongoing). Patient received any other medications within two weeks of vaccination was reported as no. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 16Apr2022, outcome "recovered" (20Apr2022) and all described as "COVID-19 treatment". Therapeutic measures were not taken as a result of vaccination failure, covid-19. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Enlargement of pancreas; A spontaneous report was received from a consumer concerning a 73-year-old male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced enlargement of pancreas.  The patient's medical history was not provided. No relevant concomitant medications were reported.    On 11 Feb 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 012M20A) of unknown route of administration on unknown location for prophylaxis of COVID-19 infection.   On 16 Mar 2021, the patient received their second of two planned doses of mRNA-1273 (Lot number: 038A21A) of unknown route of administration on unknown location for prophylaxis of COVID-19 infection.    On 08 Mar 2021 a CAT Scan was performed, and it showed an enlargement of pancreas. The reviewer told him they should perform a MRI to confirm  what they have seen.   Action taken with mRNA-1273 in response to the event was not applicable.   Outcome of the event of enlargement of pancreas was not resolved at the time of report.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
This spontaneous report was received from a certified medical assistant and refers to a patient of unknown age and gender. There was no information about patient's pertinent medical history, concomitant medications and drug reactions or allergies reported. On 12-OCT-2015, the patient was vaccinated with an improperly stored dose of M-M-R II recombinant human albumin (rHA) status (lot# J016232, expiration date, dose, anatomical location and route of administration were not reported). The reason for the temperature excursion was, because the daily vaccine counts caused the storage unit to have temperature fluctuations because of door opening. No adverse events were reported. This is one of the several reports received from the same reporter. Additional information is not expected, as no further information is available.
"Error occurred when administering a dose of Pediatric Pfizer Bivalent vaccine. Clinic staff did not dilute vaccine vial prior to administration and so patient received concentrated vaccine. Estimated dose administered ~28 mcg rather than intended 10 mcg.  Patient/caregiver did not report any adverse event."
Had lacunar stroke - diagnosed by brain MRI - hospilatized for 3 days. Tingling and numbness left leg, left hand, left side of the torso, left side of the face.
Nausea, fever and chills; Fever; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration in the left arm on 27Apr2021 at 07:30 (at the age of 39-year-old), as a single dose for COVID-19 immunisation. Medical history included immune thrombocytopenic purpura. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received erythromycin (MANUFACTURER UNKNOWN) for unspecified indication from unknown date and experienced drug allergy and received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 05Apr2021 at 07:30 (at the age of 39-year-old), as a single dose for COVID-19 immunisation. On 27Apr2021 at 18:00, the patient experienced nausea, fever and chills. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event nausea, fever and chills was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
VERTIGO, started April 6, 4 a.m. dizziness, ringing ears, nauseated, fatigue, chills,
This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID diagnosis after vaccination) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID diagnosis after vaccination). At the time of the report, COVID-19 (COVID diagnosis after vaccination) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Information has been received from a physician concerning an 18 year old male patient who on 23-DEC-1991 was vaccinated with the first dose of MMR II.  On 02-JUL-1994, the patient was vaccinated with the second dose of MMR II.  On 02-DEC-2009 the patient experienced parotitis on the left side.  The patient did not experience fever.  The patient sought unspecified medical attention.  On 04-DEC-2009, the patient was diagnosed as mumps.  At the time of the report, the patient's status was unknown.  Follow up information has been received indicating that the 18 year old male patient (also reported as 19 year old) was vaccinated with his first dose of MMR II on 23-DEC-1991 and on 02-JUL-1994, was vaccinated with the second dose of MMR II.  On 19-JAN-2010 the patient experienced mumps (previously reported as 02-DEC-2009).  The patient was diagnosed on 20-JAN-2010, signs and symptoms included cough for 3 days and swelling on left side on the neck.  The patient's first blood work was performed on 20-JAN-2010 (results not provided).  Additional information is not expected.
Light headedness, ongoing (started ~1 hour ago). I don't know if it's related to vaccine; I regularly experience presyncope with various triggers.
patient complains of red hands and itchy leg. went to dr and received prescriptions for benadryl, triamcinolone cream and prednisone
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Information regarding medical history, concurrent conditions and concomitant medications was not provided. On or about 21-OCT-2014, the patient was inoculated with ZOSTAVAX at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. In 2016, the patient was treated by a physician for a vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of ZOSTAVAX, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. 13-JUL-2013. This is a correction. The patient tab was updated with source information. The narrative was updated with minor changes to the wording. Additional information has been requested.
pt recvd vax; devel red areas & nodules at inject site, lasting 2 wks or longer;exp rxn following immun on 18apr94;
Patients mother called on 04/10/2013 and complained that child has had diarrhea since 04/05/2013, one day post vaccines. Mother states that patient had a fever on 04/05/2013 and it went away and he has had 3-4 episodes of diarrhea a day for everyday and very gassy. Mother was told to bring child in. Baby was weighed and examined and had positive weight gain, good urine output, no fever and no vomiting but continues to vomit. MD told mom to to start baby on alimentum formula, MYLICON for the gas and Probiotics. Mother started regimen and no change until the beginning of may as per mother.